NASDAQ · ALLR
Allarity Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ALLR: Nov 13, 2026
Allarity Therapeutics, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.19.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Dec 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Mar 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Jun 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks- RTTNews · Oct 30, 8:52 AM EDTAllarity Therapeutics Signs First Revenue-Generating CLIA Services Deal; Stock Down(RTTNews) – Allarity Therapeutics, Inc. (ALLR) announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy, marking an initial step toward expanding recurring revenue opportunities.
- Zacks · Oct 9, 8:55 AM EDTHere's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock NowAfter losing some value lately, a hammer chart pattern has been formed for Allarity Therapeutics, Inc. (ALLR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- RTTNews · Oct 5, 9:54 AM EDTValion Chair Jensen Outlines Focus On Entolimod Development; Stock Down(RTTNews) – Valion Bio, Inc. (VBIO), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, highlighted the strategic priorities of its new Board Chair, Thomas H. Jensen, as the company advanc
- RTTNews · Sep 15, 8:36 AM EDTAllarity Gets Japanese Patent For Stenoparib DRP Companion Diagnostic; Protection Through 2039(RTTNews) – Allarity Therapeutics, Inc. (ALLR), a Phase 2 clinical-stage pharmaceutical company developing personalized cancer treatments, announced that the Japan Patent Office has granted a key patent covering its stenoparib-specific Drug Response Predictor (DRP) companion diag
- RTTNews · Aug 19, 5:29 AM EDTAllarity Q2 Loss Expands On Higher Expenses; Stock Down(RTTNews) – Allarity Therapeutics, Inc. (ALLR), a clinical-stage precision medicine company, recently released second quarter reports highlighting a wider loss from last year due to higher expenses, associated with multiple factors.
- Zacks · Jul 22, 9:40 AM EDTAre Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year?Here is how Allarity Therapeutics, Inc. (ALLR) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
- Zacks · Jul 6, 9:40 AM EDTIs Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
- Zacks · Jun 19, 9:40 AM EDTIs Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?Here is how Allarity Therapeutics, Inc. (ALLR) and Alterity Therapeutics Limited – Sponsored ADR (ATHE) have performed compared to their sector so far this year.
- RTTNews · May 18, 9:44 AM EDTAllarity Records $2 Mln Net Loss In Q1; Initiates Phase 2 Dosing Of Stenoparib In Lung Cancer(RTTNews) – Allarity Therapeutics Inc. (ALLR), a clinical-stage pharmaceutical company, on Friday announced its first quarter financial results, and provided updates on clinical trials for stenoparib in treating cancer.
- Zacks · May 18, 9:40 AM EDTAre Medical Stocks Lagging Bioventus (BVS) This Year?Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
- RTTNews · May 5, 8:50 AM EDTAllarity Pushes Stenoparib Toward Phase 3 Readiness As Manufacturing Progresses; Stock Up(RTTNews) – Allarity Therapeutics, Inc. (ALLR) said it is moving Stenoparib closer to pivotal-stage development as the company's Phase 3 manufacturing campaign progresses on schedule, marking a key step toward preparing the drug for a potential registrational trial in advanced ov
- RTTNews · Apr 22, 6:13 AM EDTAllarity's Stenoparib Shows Promise In Colorectal And Ovarian Cancer(RTTNews) – Allarity Therapeutics, Inc. (ALLR) presented two new posters at the AACR Annual Meeting 2026 highlighting the potential Stenoparib (2X-121) in colorectal and ovarian cancer.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Allarity Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.